{"created_at":"Fri Apr 11 09:19:20 +0000 2014","id":454549248693272576,"id_str":"454549248693272576","text":"RT @abbvie: $ABBV presents detailed SAPPHIRE-I data for an investigational regimen in treatment-naive GT1 #HCV patients at #EASL http:\/\/t.c\u2026","source":"\u003ca href=\"http:\/\/twitter.com\/download\/iphone\" rel=\"nofollow\"\u003eTwitter for iPhone\u003c\/a\u003e","truncated":false,"in_reply_to_status_id":null,"in_reply_to_status_id_str":null,"in_reply_to_user_id":null,"in_reply_to_user_id_str":null,"in_reply_to_screen_name":null,"user":{"id":2234245246,"id_str":"2234245246","name":"Jan","screen_name":"jlo354","location":"","url":null,"description":null,"protected":false,"followers_count":4,"friends_count":62,"listed_count":0,"created_at":"Fri Dec 20 05:38:21 +0000 2013","favourites_count":2,"utc_offset":null,"time_zone":null,"geo_enabled":false,"verified":false,"statuses_count":22,"lang":"no","contributors_enabled":false,"is_translator":false,"is_translation_enabled":false,"profile_background_color":"C0DEED","profile_background_image_url":"http:\/\/abs.twimg.com\/images\/themes\/theme1\/bg.png","profile_background_image_url_https":"https:\/\/abs.twimg.com\/images\/themes\/theme1\/bg.png","profile_background_tile":false,"profile_image_url":"http:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_2_normal.png","profile_image_url_https":"https:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_2_normal.png","profile_link_color":"0084B4","profile_sidebar_border_color":"C0DEED","profile_sidebar_fill_color":"DDEEF6","profile_text_color":"333333","profile_use_background_image":true,"default_profile":true,"default_profile_image":true,"following":null,"follow_request_sent":null,"notifications":null},"geo":null,"coordinates":null,"place":null,"contributors":null,"retweeted_status":{"created_at":"Fri Apr 11 05:31:47 +0000 2014","id":454491984170729472,"id_str":"454491984170729472","text":"$ABBV presents detailed SAPPHIRE-I data for an investigational regimen in treatment-naive GT1 #HCV patients at #EASL http:\/\/t.co\/Ovg2rbWyIs","source":"\u003ca href=\"http:\/\/sproutsocial.com\" rel=\"nofollow\"\u003eSprout Social\u003c\/a\u003e","truncated":false,"in_reply_to_status_id":null,"in_reply_to_status_id_str":null,"in_reply_to_user_id":null,"in_reply_to_user_id_str":null,"in_reply_to_screen_name":null,"user":{"id":531892451,"id_str":"531892451","name":"AbbVie","screen_name":"abbvie","location":"","url":"http:\/\/www.abbvie.com","description":"Our passion lies in developing advanced therapies to address the world\u2019s most difficult health problems.","protected":false,"followers_count":8382,"friends_count":168,"listed_count":105,"created_at":"Wed Mar 21 03:42:59 +0000 2012","favourites_count":1,"utc_offset":-18000,"time_zone":"Central Time (US & Canada)","geo_enabled":false,"verified":true,"statuses_count":281,"lang":"en","contributors_enabled":false,"is_translator":false,"is_translation_enabled":false,"profile_background_color":"071D49","profile_background_image_url":"http:\/\/pbs.twimg.com\/profile_background_images\/752358654\/f5985d9535ef4e9782f6c74758ddc0ca.png","profile_background_image_url_https":"https:\/\/pbs.twimg.com\/profile_background_images\/752358654\/f5985d9535ef4e9782f6c74758ddc0ca.png","profile_background_tile":false,"profile_image_url":"http:\/\/pbs.twimg.com\/profile_images\/3049418526\/00a79e3ec22f0498806f4eac64df8772_normal.png","profile_image_url_https":"https:\/\/pbs.twimg.com\/profile_images\/3049418526\/00a79e3ec22f0498806f4eac64df8772_normal.png","profile_banner_url":"https:\/\/pbs.twimg.com\/profile_banners\/531892451\/1357016252","profile_link_color":"071D49","profile_sidebar_border_color":"FFFFFF","profile_sidebar_fill_color":"EFEFEF","profile_text_color":"333333","profile_use_background_image":true,"default_profile":false,"default_profile_image":false,"following":null,"follow_request_sent":null,"notifications":null},"geo":null,"coordinates":null,"place":null,"contributors":null,"retweet_count":9,"favorite_count":0,"entities":{"hashtags":[{"text":"HCV","indices":[94,98]},{"text":"EASL","indices":[111,116]}],"symbols":[{"text":"ABBV","indices":[0,5]}],"urls":[{"url":"http:\/\/t.co\/Ovg2rbWyIs","expanded_url":"http:\/\/bit.ly\/1bmJ1dL","display_url":"bit.ly\/1bmJ1dL","indices":[117,139]}],"user_mentions":[]},"favorited":false,"retweeted":false,"possibly_sensitive":false,"lang":"en"},"retweet_count":0,"favorite_count":0,"entities":{"hashtags":[{"text":"HCV","indices":[106,110]},{"text":"EASL","indices":[123,128]}],"symbols":[{"text":"ABBV","indices":[12,17]}],"urls":[{"url":"http:\/\/t.co\/Ovg2rbWyIs","expanded_url":"http:\/\/bit.ly\/1bmJ1dL","display_url":"bit.ly\/1bmJ1dL","indices":[139,140]}],"user_mentions":[{"screen_name":"abbvie","name":"AbbVie","id":531892451,"id_str":"531892451","indices":[3,10]}]},"favorited":false,"retweeted":false,"possibly_sensitive":false,"filter_level":"medium","lang":"en"}
{"created_at":"Fri Apr 11 08:56:36 +0000 2014","id":454543527653801984,"id_str":"454543527653801984","text":"RT @portefeuillefun: $ENTA. $ABBV to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hep C Patients\nh\u2026","source":"web","truncated":false,"in_reply_to_status_id":null,"in_reply_to_status_id_str":null,"in_reply_to_user_id":null,"in_reply_to_user_id_str":null,"in_reply_to_screen_name":null,"user":{"id":770904320,"id_str":"770904320","name":"Gotham City Capital","screen_name":"TravisMKnight","location":"Reno\/Los Angeles","url":null,"description":"Biotech Research Company","protected":false,"followers_count":739,"friends_count":206,"listed_count":19,"created_at":"Tue Aug 21 05:43:32 +0000 2012","favourites_count":705,"utc_offset":-25200,"time_zone":"Pacific Time (US & Canada)","geo_enabled":false,"verified":false,"statuses_count":11007,"lang":"en","contributors_enabled":false,"is_translator":false,"is_translation_enabled":false,"profile_background_color":"C0DEED","profile_background_image_url":"http:\/\/pbs.twimg.com\/profile_background_images\/378800000136303556\/cX8cild6.jpeg","profile_background_image_url_https":"https:\/\/pbs.twimg.com\/profile_background_images\/378800000136303556\/cX8cild6.jpeg","profile_background_tile":false,"profile_image_url":"http:\/\/pbs.twimg.com\/profile_images\/434839676461907968\/asp2JLIn_normal.jpeg","profile_image_url_https":"https:\/\/pbs.twimg.com\/profile_images\/434839676461907968\/asp2JLIn_normal.jpeg","profile_link_color":"0084B4","profile_sidebar_border_color":"FFFFFF","profile_sidebar_fill_color":"DDEEF6","profile_text_color":"333333","profile_use_background_image":true,"default_profile":false,"default_profile_image":false,"following":null,"follow_request_sent":null,"notifications":null},"geo":null,"coordinates":null,"place":null,"contributors":null,"retweeted_status":{"created_at":"Fri Apr 11 05:50:04 +0000 2014","id":454496582348865536,"id_str":"454496582348865536","text":"$ENTA. $ABBV to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hep C Patients\nhttp:\/\/t.co\/wbizyXpiIS","source":"\u003ca href=\"http:\/\/twitter.com\/#!\/download\/ipad\" rel=\"nofollow\"\u003eTwitter for iPad\u003c\/a\u003e","truncated":false,"in_reply_to_status_id":null,"in_reply_to_status_id_str":null,"in_reply_to_user_id":null,"in_reply_to_user_id_str":null,"in_reply_to_screen_name":null,"user":{"id":427877977,"id_str":"427877977","name":"V.S. Schulz","screen_name":"portefeuillefun","location":"D\u00fcsseldorf, Germany","url":"http:\/\/www.linkedin.com\/profile\/view?id=216278772","description":"co-manager (with @zzlangerhans) of a biopharma equity portfolio (#zzporte collaboration). physics\/mathematics finance\/controlling background.","protected":false,"followers_count":1129,"friends_count":775,"listed_count":40,"created_at":"Sun Dec 04 02:43:03 +0000 2011","favourites_count":18,"utc_offset":7200,"time_zone":"Berlin","geo_enabled":false,"verified":false,"statuses_count":10712,"lang":"en","contributors_enabled":false,"is_translator":false,"is_translation_enabled":false,"profile_background_color":"C0DEED","profile_background_image_url":"http:\/\/abs.twimg.com\/images\/themes\/theme1\/bg.png","profile_background_image_url_https":"https:\/\/abs.twimg.com\/images\/themes\/theme1\/bg.png","profile_background_tile":false,"profile_image_url":"http:\/\/pbs.twimg.com\/profile_images\/428747802114396160\/5lMQwydP_normal.jpeg","profile_image_url_https":"https:\/\/pbs.twimg.com\/profile_images\/428747802114396160\/5lMQwydP_normal.jpeg","profile_banner_url":"https:\/\/pbs.twimg.com\/profile_banners\/427877977\/1393221063","profile_link_color":"0084B4","profile_sidebar_border_color":"C0DEED","profile_sidebar_fill_color":"DDEEF6","profile_text_color":"333333","profile_use_background_image":true,"default_profile":true,"default_profile_image":false,"following":null,"follow_request_sent":null,"notifications":null},"geo":null,"coordinates":null,"place":null,"contributors":null,"retweet_count":2,"favorite_count":1,"entities":{"hashtags":[],"symbols":[{"text":"ENTA","indices":[0,5]},{"text":"ABBV","indices":[7,12]}],"urls":[{"url":"http:\/\/t.co\/wbizyXpiIS","expanded_url":"http:\/\/abbvie.mediaroom.com\/2014-04-11-AbbVie-to-Present-Detailed-Phase-III-Results-from-SAPPHIRE-I-and-SAPPHIRE-II-Studies-in-Chronic-Hepatitis-C-Patients-at-the-2014-International-Liver-Congress","display_url":"abbvie.mediaroom.com\/2014-04-11-Abb\u2026","indices":[117,139]}],"user_mentions":[]},"favorited":false,"retweeted":false,"possibly_sensitive":false,"lang":"en"},"retweet_count":0,"favorite_count":0,"entities":{"hashtags":[],"symbols":[{"text":"ENTA","indices":[21,26]},{"text":"ABBV","indices":[28,33]}],"urls":[{"url":"http:\/\/t.co\/wbizyXpiIS","expanded_url":"http:\/\/abbvie.mediaroom.com\/2014-04-11-AbbVie-to-Present-Detailed-Phase-III-Results-from-SAPPHIRE-I-and-SAPPHIRE-II-Studies-in-Chronic-Hepatitis-C-Patients-at-the-2014-International-Liver-Congress","display_url":"abbvie.mediaroom.com\/2014-04-11-Abb\u2026","indices":[139,140]}],"user_mentions":[{"screen_name":"portefeuillefun","name":"V.S. Schulz","id":427877977,"id_str":"427877977","indices":[3,19]}]},"favorited":false,"retweeted":false,"possibly_sensitive":false,"filter_level":"medium","lang":"en"}
{"created_at":"Fri Apr 11 19:21:16 +0000 2014","id":454700730176135168,"id_str":"454700730176135168","text":"RT @abbvie: Results from $ABBV phase III program presented at #EASL for GT1 treatment-na\u00efve\/experienced #HCV patients http:\/\/t.co\/Ovg2rbWyIs","source":"\u003ca href=\"http:\/\/twitter.com\/download\/android\" rel=\"nofollow\"\u003eTwitter for Android\u003c\/a\u003e","truncated":false,"in_reply_to_status_id":null,"in_reply_to_status_id_str":null,"in_reply_to_user_id":null,"in_reply_to_user_id_str":null,"in_reply_to_screen_name":null,"user":{"id":30885472,"id_str":"30885472","name":"Tim Teater","screen_name":"TimTeater","location":"Gurnee, IL","url":null,"description":null,"protected":false,"followers_count":40,"friends_count":43,"listed_count":0,"created_at":"Mon Apr 13 15:29:13 +0000 2009","favourites_count":47,"utc_offset":null,"time_zone":null,"geo_enabled":true,"verified":false,"statuses_count":262,"lang":"en","contributors_enabled":false,"is_translator":false,"is_translation_enabled":false,"profile_background_color":"C0DEED","profile_background_image_url":"http:\/\/abs.twimg.com\/images\/themes\/theme1\/bg.png","profile_background_image_url_https":"https:\/\/abs.twimg.com\/images\/themes\/theme1\/bg.png","profile_background_tile":false,"profile_image_url":"http:\/\/pbs.twimg.com\/profile_images\/200261195\/orl09_normal.jpg","profile_image_url_https":"https:\/\/pbs.twimg.com\/profile_images\/200261195\/orl09_normal.jpg","profile_link_color":"0084B4","profile_sidebar_border_color":"C0DEED","profile_sidebar_fill_color":"DDEEF6","profile_text_color":"333333","profile_use_background_image":true,"default_profile":true,"default_profile_image":false,"following":null,"follow_request_sent":null,"notifications":null},"geo":null,"coordinates":null,"place":null,"contributors":null,"retweeted_status":{"created_at":"Fri Apr 11 09:15:01 +0000 2014","id":454548160027705344,"id_str":"454548160027705344","text":"Results from $ABBV phase III program presented at #EASL for GT1 treatment-na\u00efve\/experienced #HCV patients http:\/\/t.co\/Ovg2rbWyIs","source":"\u003ca href=\"http:\/\/sproutsocial.com\" rel=\"nofollow\"\u003eSprout Social\u003c\/a\u003e","truncated":false,"in_reply_to_status_id":null,"in_reply_to_status_id_str":null,"in_reply_to_user_id":null,"in_reply_to_user_id_str":null,"in_reply_to_screen_name":null,"user":{"id":531892451,"id_str":"531892451","name":"AbbVie","screen_name":"abbvie","location":"","url":"http:\/\/www.abbvie.com","description":"Our passion lies in developing advanced therapies to address the world\u2019s most difficult health problems.","protected":false,"followers_count":8394,"friends_count":168,"listed_count":106,"created_at":"Wed Mar 21 03:42:59 +0000 2012","favourites_count":1,"utc_offset":-18000,"time_zone":"Central Time (US & Canada)","geo_enabled":false,"verified":true,"statuses_count":282,"lang":"en","contributors_enabled":false,"is_translator":false,"is_translation_enabled":false,"profile_background_color":"071D49","profile_background_image_url":"http:\/\/pbs.twimg.com\/profile_background_images\/752358654\/f5985d9535ef4e9782f6c74758ddc0ca.png","profile_background_image_url_https":"https:\/\/pbs.twimg.com\/profile_background_images\/752358654\/f5985d9535ef4e9782f6c74758ddc0ca.png","profile_background_tile":false,"profile_image_url":"http:\/\/pbs.twimg.com\/profile_images\/3049418526\/00a79e3ec22f0498806f4eac64df8772_normal.png","profile_image_url_https":"https:\/\/pbs.twimg.com\/profile_images\/3049418526\/00a79e3ec22f0498806f4eac64df8772_normal.png","profile_banner_url":"https:\/\/pbs.twimg.com\/profile_banners\/531892451\/1357016252","profile_link_color":"071D49","profile_sidebar_border_color":"FFFFFF","profile_sidebar_fill_color":"EFEFEF","profile_text_color":"333333","profile_use_background_image":true,"default_profile":false,"default_profile_image":false,"following":null,"follow_request_sent":null,"notifications":null},"geo":null,"coordinates":null,"place":null,"contributors":null,"retweet_count":13,"favorite_count":2,"entities":{"hashtags":[{"text":"EASL","indices":[50,55]},{"text":"HCV","indices":[92,96]}],"symbols":[{"text":"ABBV","indices":[13,18]}],"urls":[{"url":"http:\/\/t.co\/Ovg2rbWyIs","expanded_url":"http:\/\/bit.ly\/1bmJ1dL","display_url":"bit.ly\/1bmJ1dL","indices":[106,128]}],"user_mentions":[]},"favorited":false,"retweeted":false,"possibly_sensitive":false,"lang":"en"},"retweet_count":0,"favorite_count":0,"entities":{"hashtags":[{"text":"EASL","indices":[62,67]},{"text":"HCV","indices":[104,108]}],"symbols":[{"text":"ABBV","indices":[25,30]}],"urls":[{"url":"http:\/\/t.co\/Ovg2rbWyIs","expanded_url":"http:\/\/bit.ly\/1bmJ1dL","display_url":"bit.ly\/1bmJ1dL","indices":[118,140]}],"user_mentions":[{"screen_name":"abbvie","name":"AbbVie","id":531892451,"id_str":"531892451","indices":[3,10]}]},"favorited":false,"retweeted":false,"possibly_sensitive":false,"filter_level":"medium","lang":"en"}
